While clinical data focuses heavily on body mass index (BMI) or percentage of total body weight loss, the IWQOL-Lite-CT provides measurable quantitative data on how weight impacts a person's life across two core domains:
The IWQOL-Lite-CT has been deployed in numerous clinical trials for weight loss medications, including those for (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Mounjaro and Zepbound), measuring improvements in physical function and psychosocial well-being alongside weight loss. Recent studies have used it to show that weight loss has a direct and significant positive effect on IWQOL-Lite-CT scores across the physical, psychosocial, and total score domains. iwqol-lite-ct pdf
Whether used in its PDF form or as part of a digital ecosystem, the IWQOL-Lite-CT continues to advance our understanding of how weight affects quality of life and how new treatments can make a meaningful difference from the patient's perspective. While clinical data focuses heavily on body mass
Because it is highly sensitive to incremental weight loss or weight gain, researchers rely heavily on it to measure the real-world benefits of anti-obesity medications, bariatric surgeries, and intensive lifestyle interventions. Accessing the IWQOL-Lite-CT PDF Because it is highly sensitive to incremental weight
The is a refined, patient-reported outcome (PRO) instrument designed specifically for use in clinical research. It measures how excess weight affects an individual’s physical and psychosocial functioning.
Once approved, you will receive a digital package that includes: